CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy

Pharmacology and Therapeutics

Volumn 142, Issue 1, 2014, Pages 1-10

  McNeely, S ^a   Beckmann, R ^a   Bence Lin, A K ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Checkpoint kinase 1; CHK1; DNA damage response; DNA replication; WEE1

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AR 458323; CAMPTOTHECIN; CBP 501; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITORS; CHECKPOINT KINASE 2; CISPLATIN; CYTARABINE; DSB XL 844; FIRTECAN; FOLIC ACID ANTAGONIST; GDC 0425; GDC 0575; GEMCITABINE; HYDROXYUREA; IRINOTECAN; MK 1775; PEMETREXED; PF 00477736; PROTEIN SERINE THREONINE KINASE INHIBITOR; RABUSERTIB; SAR 020106; SB 21807; SCH 900776; SMALL INTERFERING RNA; TCS 2312; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 844;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; DNA DAMAGE; DNA REPLICATION; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

CHECKPOINT KINASE 1; CHK1; DNA DAMAGE RESPONSE; DNA REPLICATION; WEE1;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; DNA DAMAGE; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84896735637     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.10.005     Document Type: Review

References (111)

1. T. Akiyama, T. Yoshida, T. Tsujita, M. Shimizu, T. Mizukami, and M. Okabe et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells Cancer Res 57 1997 1495 1501
2. S. Ashwell, J.W. Janetka, and S. Zabludoff Keeping checkpoint kinases in line: New selective inhibitors in clinical trials Expert Opin Investig Drugs 17 2008 1331 1340
3. S. Backert, M. Gelos, U. Kobalz, M.L. Hanski, C. Bohm, and B. Mann et al. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array Int J Cancer 82 1999 868 874
4. E.M. Bahassi, J.L. Ovesen, A.L. Riesenberg, W.Z. Bernstein, P.E. Hasty, and P.J. Stambrook The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage Oncogene 27 2008 3977 3985
5. M. Bartucci, S. Svensson, P. Romania, R. Dattilo, M. Patrizii, and M. Signore et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy Cell Death Differ 19 2012 768 778
6. H. Beck, V. Nahse, M.S. Larsen, P. Groth, T. Clancy, and M. Lees et al. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase J Cell Biol 188 2010 629 638
7. H. Beck, V. Nahse-Kumpf, M.S. Larsen, K.A. O'Hanlon, S. Patzke, and C. Holmberg et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption Mol Cell Biol 32 2012 4226 4236
8. J. Bendell, F. Janku, J. Infante, S. Jones, H. Burris, and L. Golden et al. Dose and schedule determination of the Chk1/2 inhibitor LY2606368 in patients with solid tumors Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10 2013 AACR Washington, DC. Philadelphia (PA) (Abstract nr LB-200)
9. A. Bhattacharya, U. Schmitz, O. Wolkenhauer, M. Schonherr, Y. Raatz, and M. Kunz Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma Oncogene 32 2013 3175 3183
10. A. Blasina, J. Hallin, E. Chen, M.E. Arango, E. Kraynov, and J. Register et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 Mol Cancer Ther 7 2008 2394 2404
11. N. Brega, G. McArthur, C. Britten, S. Wong, E. Wang, and K. Wilner et al. Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase J Clin Oncol 28 15s 2010 (Suppl.; abstr 3062)
12. K. Brooks, V. Oakes, B. Edwards, M. Ranall, P. Leo, and S. Pavey et al. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress Oncogene 32 2013 788 796
13. C. Bryant, S. Stokes, and A. Massey Chk1 inhibition as a novel therapeutic strategy for treating triple negative breast and ovarian cancers Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL Cancer Res 71 2011
14. N. Bucher, and C.D. Britten G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer Br J Cancer 98 2008 523 528
15. E. Calvo, N. Dickgreber, S. Hynes, R. Decker, E. Kumm, and U. Ohnmacht et al. Dose determination of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer Poster presented at EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics; November 6-9, 2012; Dublin, Ireland 2012 (abstract nbr 586)
16. E. Calvo, D. Richards, F. Braiteh, D. Von Hoff, R. McWilliams, and C. Becerra et al. Dose determination of LY2603618, a Chk1 inhibitor, administered in combination with gemcitabine in patients with advanced cancer Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA Mol Cancer Ther 10 2011 (Abstract nr A94)
17. L. Carrassa, R. Chila, M. Lupi, F. Ricci, C. Celenza, and M. Mazzoletti et al. Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo Cell Cycle 11 2012 2507 2517
18. L. Carrassa, Y. Sanchez, E. Erba, and G. Damia U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint J Cell Mol Med 13 2009 1565 1576
19. C.C. Chen, R.D. Kennedy, S. Sidi, A.T. Look, and A. D'Andrea CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors Mol Cancer 8 2009 24
20. Z. Chen, Z. Xiao, J. Chen, S.C. Ng, T. Sowin, and H. Sham et al. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint Mol Cancer Ther 2 2003 543 548
21. A. Ciccia, and S.J. Elledge The DNA damage response: Making it safe to play with knives Mol Cell 40 2010 179 204
22. K.A. Cole, J. Huggins, M. Laquaglia, C.E. Hulderman, M.R. Russell, and K. Bosse et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma Proc Natl Acad Sci U S A 108 2011 3336 3341
23. D. Cortez, S. Guntuku, J. Qin, and S.J. Elledge ATR and ATRIP: Partners in checkpoint signaling Science 294 2001 1713 1716
24. Y. Dai, S. Chen, X.Y. Pei, J.A. Almenara, L.B. Kramer, and C.A. Venditti et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells Blood 112 2008 2439 2449
25. Y. Dai, and S. Grant New insights into checkpoint kinase 1 in the DNA damage response signaling network Clin Cancer Res 16 2010 376 383
26. Y. Dai, P. Khanna, S. Chen, X.Y. Pei, P. Dent, and S. Grant Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation Blood 109 2007 4415 4423
27. Y. Dai, C. Yu, V. Singh, L. Tang, Z. Wang, and R. McInistry et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells Cancer Res 61 2001 5106 5115
28. A. Daud, G. Springett, D. Mendelson, P. Munster, J. Goldman, and J. Strosberg et al. A phase I dose-escalation study of Sch 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors J Clin Oncol 28 15s 2010 (Suppl.; abstr 3064)
29. K.D. Davies, P.L. Cable, J.E. Garrus, F.X. Sullivan, I. von Carlowitz, and Y.L. Huerou et al. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation Cancer Biol Ther 12 2011 788 796
30. K.D. Davies, M.J. Humphries, F.X. Sullivan, I. von Carlowitz, Y. Le Huerou, and P.J. Mohr et al. Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo Oncol Res 19 2011 349 363
31. S. Delacroix, J.M. Wagner, M. Kobayashi, K. Yamamoto, and L.M. Karnitz The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1 Genes Dev 21 2007 1472 1477
32. P. Dent, Y. Tang, A. Yacoub, Y. Dai, P.B. Fisher, and S. Grant CHK1 inhibitors in combination chemotherapy: Thinking beyond the cell cycle Mol Interv 11 2011 133 140
33. R. Dominguez-Kelly, Y. Martin, S. Koundrioukoff, M.E. Tanenbaum, V.A. Smits, and R.H. Medema et al. Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease J Cell Biol 194 2011 567 579
34. C. Feijoo, C. Hall-Jackson, R. Wu, D. Jenkins, J. Leitch, and D.M. Gilbert et al. Activation of mammalian Chk1 during DNA replication arrest: A role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing J Cell Biol 154 2001 913 923
35. J.V. Forment, M. Blasius, I. Guerini, and S.P. Jackson Structure-specific DNA endonuclease Mus81/Eme1 generates DNA damage caused by Chk1 inactivation PLoS One 6 2011 e23517
36. A.D. Guertin, M.M. Martin, B. Roberts, M. Hurd, X. Qu, and N.R. Miselis et al. Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition Cancer Cell Int 12 2012 45
37. T.J. Guzi, K. Paruch, M.P. Dwyer, M. Labroli, F. Shanahan, and N. Davis et al. Targeting the replication checkpoint using Sch 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening Mol Cancer Ther 10 2011 591 602
38. K. Hanada, M. Budzowska, S.L. Davies, E. van Drunen, H. Onizawa, and H.B. Beverloo et al. The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks Nat Struct Mol Biol 14 2007 1096 1104
39. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: The next generation Cell 144 2011 646 674
40. T.P. Heffernan, K. Unsal-Kacmaz, A.N. Heinloth, D.A. Simpson, R.S. Paules, and A. Sancar et al. Cdc7-Dbf4 and the human S checkpoint response to UVC J Biol Chem 282 2007 9458 9468
41. A. Ho, J. Bendell, J. Cleary, G. Schwartz, H. Burris, and P. Oakes et al. Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors J Clin Oncol 29 2011 (Suppl.; abstr 3033)
42. S.P. Jackson, and J. Bartek The DNA-damage response in human biology and disease Nature 461 2009 1071 1078
43. R.M. Jones, and E. Petermann Replication fork dynamics and the DNA damage response Biochem J 443 2012 13 26
44. J.E. Karp, B.M. Thomas, J.M. Greer, C. Sorge, S.D. Gore, and K.W. Pratz et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias Clin Cancer Res 18 2012 6723 6731
45. J.M. Kim, M. Yamada, and H. Masai Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development Mutat Res 532 2003 29 40
46. D. Komander, G.S. Kular, J. Bain, M. Elliott, D.R. Alessi, and D.M. Van Aalten Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition Biochem J 375 2003 255 262
47. A. Kramer, N. Mailand, C. Lukas, R.G. Syljuasen, C.J. Wilkinson, and E.A. Nigg et al. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase Nat Cell Biol 6 2004 884 891
48. K. Labib How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes Dev 24 2010 1208 1219
49. M.H. Lam, Q. Liu, S.J. Elledge, and J.M. Rosen Chk1 is haploinsufficient for multiple functions critical to tumor suppression Cancer Cell 6 2004 45 59
50. M.F. Lavin ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks Oncogene 26 2007 7749 7758
51. J. Lee, A. Kumagai, and W.G. Dunphy Positive regulation of Wee1 by Chk1 and 14-3-3 proteins Mol Biol Cell 12 2001 551 563
52. Q. Liu, S. Guntuku, X.S. Cui, S. Matsuoka, D. Cortez, and K. Tamai et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint Genes Dev 14 2000 1448 1459
53. Y. Luo, S.K. Rockow-Magnone, P.E. Kroeger, L. Frost, Z. Chen, and E.K. Han et al. Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism Neoplasia 3 2001 411 419
54. C.X. Ma, S. Cai, S. Li, C.E. Ryan, Z. Guo, and W.T. Schaiff et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models J Clin Invest 122 2012 1541 1552
55. C.X. Ma, J.W. Janetka, and H. Piwnica-Worms Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics Trends Mol Med 17 2011 88 96
56. M. Marshall, D. Barda, D. Barnard, K. Cox, H.B. Diaz, and C. King et al. Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase 1 clinical trials [abstract] Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics - Nov 15-19, 2009; Boston, MA Mol Cancer Ther 8 2009 B248
57. M. Marshall, C. King, D. Barnard, H.B. Diaz, D. Barda, and A. Bence Characterization and preclinical development of LY2606368, a second generation Chk1 inhibitor Poster presented at EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics; November 16-19, 2010; Berlin, Germany 2010 (Abstract nr 194)
58. D.J. Matthews, F.M. Yakes, J. Chen, M. Tadano, L. Bornheim, and D.O. Clary et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo Cell Cycle 6 2007 104 110
59. A. Maya-Mendoza, E. Petermann, D.A. Gillespie, K.W. Caldecott, and D.A. Jackson Chk1 regulates the density of active replication origins during the vertebrate S phase EMBO J 26 2007 2719 2731
60. D. McIntosh, and J.J. Blow Dormant origins, the licensing checkpoint, and the response to replicative stresses Cold Spring Harb Perspect Biol 4 2012
61. S. McNeely, T. Burke, S. Durland-Busbice, S. Barnard, M. Marshall, and A. Bence et al. LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA Mol Cancer Ther 10 2011 (Abstract nr A108)
62. S. McNeely, C. Conti, T. Sheikh, H. Patel, S. Zabludoff, and Y. Pommier et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase Cell Cycle 9 2010 995 1004
63. J.B. Mitchell, R. Choudhuri, K. Fabre, A.L. Sowers, D. Citrin, and S.D. Zabludoff et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762 Clin Cancer Res 16 2010 2076 2084
64. C. Mitchell, H.A. Hamed, N. Cruickshanks, Y. Tang, M.D. Bareford, and N. Hubbard et al. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death Cancer Biol Ther 12 2011 215 228
65. R. Montano, I. Chung, K.M. Garner, D. Parry, and A. Eastman Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites Mol Cancer Ther 11 2012 427 438
66. M. Murga, S. Campaner, A.J. Lopez-Contreras, L.I. Toledo, R. Soria, and M.F. Montana et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors Nat Struct Mol Biol 18 2011 1331 1335
67. E.A. Nam, and D. Cortez ATR signalling: More than meeting at the fork Biochem J 436 2011 527 536
68. H. Niida, S. Tsuge, Y. Katsuno, A. Konishi, N. Takeda, and M. Nakanishi Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe J Biol Chem 280 2005 39246 39252
69. M.J. O'Connell, J.M. Raleigh, H.M. Verkade, and P. Nurse Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation EMBO J 16 1997 545 554
70. V. Oza, S. Ashwell, L. Almeida, P. Brassil, J. Breed, and C. Deng et al. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3- yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas J Med Chem 55 2012 5130 5142
71. S. Peddibhotla, M.H. Lam, M. Gonzalez-Rimbau, and J.M. Rosen The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis Proc Natl Acad Sci U S A 106 2009 5159 5164
72. X.-Y. Pei, Y. Dai, S. Chen, W. Bodie, L. Kramer, and P. Dent et al. The MEK1/2 inhibitor AZD6244 (ARRY-142886) interacts synergistically with the novel Chk1 inhibitor AZD7762 to induce apoptosis in human multiple myeloma cells AACR Meeting Abstracts 2008 (LB-103)
73. X.Y. Pei, Y. Dai, S. Tenorio, J. Lu, H. Harada, and P. Dent et al. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism Blood 110 2007 2092 2101
74. X.Y. Pei, Y. Dai, L.E. Youssefian, S. Chen, W.W. Bodie, and Y. Takabatake et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2 Blood 118 2011 5189 5200
75. C.Y. Peng, P.R. Graves, R.S. Thoma, Z. Wu, A.S. Shaw, and H. Piwnica-Worms Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216 Science 277 1997 1501 1505
76. E. Petermann, A. Maya-Mendoza, G. Zachos, D.A. Gillespie, D.A. Jackson, and K.W. Caldecott Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase Mol Cell Biol 26 2006 3319 3326
77. E. Petermann, M. Woodcock, and T. Helleday Chk1 promotes replication fork progression by controlling replication initiation Proc Natl Acad Sci U S A 107 2010 16090 16095
78. M.R. Russell, K. Levin, J. Rader, L. Belcastro, Y. Li, and D. Martinez et al. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma Cancer Res 73 2013 776 784
79. E. Sausville, P. LoRusso, M. Carducci, P. Barker, F. Agbo, and P. Oakes Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors J Clin Oncol 29 2011 (Suppl.; abstr 3058)
80. E.L. Schenk, B.D. Koh, K.S. Flatten, K.L. Peterson, D. Parry, and A.D. Hess et al. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro Clin Cancer Res 18 2012 5364 5373
81. E. Schmitt, R. Boutros, C. Froment, B. Monsarrat, B. Ducommun, and C. Dozier CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage J Cell Sci 119 2006 4269 4275
82. T. Seto, T. Esaki, F. Hirai, S. Arita, K. Nosaki, and A. Makiyama et al. Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors J Clin Oncol 30 2012 (Suppl.; abstr 3045)
83. S.K. Sha, T. Sato, H. Kobayashi, M. Ishigaki, S. Yamamoto, and H. Sato et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint Mol Cancer Ther 6 2007 147 153
84. D. Shechter, V. Costanzo, and J. Gautier ATR and ATM regulate the timing of DNA replication origin firing Nat Cell Biol 6 2004 648 655
85. C.S. Sorensen, L.T. Hansen, J. Dziegielewski, R.G. Syljuasen, C. Lundin, and J. Bartek et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair Nat Cell Biol 7 2005 195 201
86. C.S. Sorensen, and R.G. Syljuasen Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication Nucleic Acids Res 40 2012 477 486
87. C.S. Sorensen, R.G. Syljuasen, J. Falck, T. Schroeder, L. Ronnstrand, and K.K. Khanna et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A Cancer Cell 3 2003 247 258
88. P. Stephens, A. Massey, R. Plummer, and N. Curtin Single agent activity of the novel checkpoint 1 kinase inhibitor V158411 Poster presented at the 24th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics' in Dublin on 6-9 November 2012 2012 (Abstract nr 277)
89. R.G. Syljuasen, C.S. Sorensen, L.T. Hansen, K. Fugger, C. Lundin, and F. Johansson et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage Mol Cell Biol 25 2005 3553 3562
90. S. Tanaka, and H. Araki Regulation of the initiation step of DNA replication by cyclin-dependent kinases Chromosoma 119 2010 565 574
91. J. Tang, R.L. Erikson, and X. Liu Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1) Proc Natl Acad Sci U S A 103 2006 11964 11969
92. W.R. Taylor, and G.R. Stark Regulation of the G2/M transition by p53 Oncogene 20 2001 1803 1815
93. R. Thompson, and A. Eastman The cancer therapeutic potential of Chk1 inhibitors: How mechanistic studies impact clinical trial design Br J Clin Pharmacol 76 2013 358 369
94. R. Thompson, R. Montano, and A. Eastman The Mre11 nuclease is critical for the sensitivity of cells to Chk1 inhibition PLoS One 7 8 2012 e44021 10.1371/journal.pone.0044021
95. E. Tili, J.J. Michaille, D. Wernicke, H. Alder, S. Costinean, and S. Volinia et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer Proc Natl Acad Sci U S A 108 2011 4908 4913
96. L.I. Toledo, M. Murga, and O. Fernandez-Capetillo Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs Mol Oncol 5 2011 368 373
97. A.N. Tse, R. Carvajal, and G.K. Schwartz Targeting checkpoint kinase 1 in cancer therapeutics Clin Cancer Res 13 2007 1955 1960
98. A.N. Tse, K.G. Rendahl, T. Sheikh, H. Cheema, K. Aardalen, and M. Embry et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo Clin Cancer Res 13 2007 591 602
99. J.M. Wagner, and L.M. Karnitz Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival Mol Pharmacol 76 2009 208 214
100. M.I. Walton, P.D. Eve, A. Hayes, M. Valenti, A. De Haven Brandon, and G. Box et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106 Mol Cancer Ther 9 2010 89 100
101. X. Wang, R.D. Kennedy, K. Ray, P. Stuckert, T. Ellenberger, and A.D. D'Andrea Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway Mol Cell Biol 27 2007 3098 3108
102. M. Weinreich, and B. Stillman Cdc7p-Dbf4p kinase binds to chromatin during S phase and is regulated by both the APC and the RAD53 checkpoint pathway EMBO J 18 1999 5334 5346
103. G.J. Weiss, R.C. Donehower, T. Iyengar, R.K. Ramanathan, K. Lewandowski, and E. Westin et al. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer Invest New Drugs 31 2013 136 144
104. D. Wilsker, E. Petermann, T. Helleday, and F. Bunz Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control Proc Natl Acad Sci U S A 105 2008 20752 20757
105. W. Wu, B. Chen, A. Bence, S. Um, B. Yan, and J. Starling et al. Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model Cancer Res 72 2012 (Abstract nr 177)
106. S.D. Zabludoff, C. Deng, M.R. Grondine, A.M. Sheehy, S. Ashwell, and B.L. Caleb et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol Cancer Ther 7 2008 2955 2966
107. G. Zachos, E.J. Black, M. Walker, M.T. Scott, P. Vagnarelli, and W.C. Earnshaw et al. Chk1 is required for spindle checkpoint function Dev Cell 12 2007 247 260
108. G. Zachos, M.D. Rainey, and D.A. Gillespie Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects EMBO J 22 2003 713 723
109. S. Zenvirt, N. Kravchenko-Balasha, and A. Levitzki Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents Oncogene 29 2010 6149 6159
110. H. Zhao, J.L. Watkins, and H. Piwnica-Worms Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints Proc Natl Acad Sci U S A 99 2002 14795 14800
111. G. Zhi, J.B. Wilson, X. Chen, D.S. Krause, Y. Xiao, and N.J. Jones et al. Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction Cancer Res 69 2009 8775 8783